Table 3. Antimicrobial resistance profile of E. coli isolates from UC, CD, and control groups.
| Antibiotics | Resistant E. coli isolates | ||
|---|---|---|---|
| UC (n=30) | CD (n=30) | Controls (n=20) | |
| N (%) | N (%) | N (%) | |
| Ampicillin | 30 (100%) | 30 (100%) | 20 (100%) |
| Piperacillin | 28 (93.3%) | 21 (70%) | 16 (80%) |
| Cefazolin | 30 (100%) | 30 (100%) | 20 (100%) |
| Cefuroxime | 30 (100%) | 28 (93.3%) | 9 (45%) |
| Ceftriaxone | 28 (93.3%) | 26 (86.7%) | 9 (45%) |
| Cefotaxime | 28 (93.3%) | 26 (86.7%) | 9 (45%) |
| Ceftazidime | 28 (93.3%) | 26 (86.7%) | 7 (35%) |
| Cefepime | 18 (60%) | 26 (86.7%) | 4 (20%) |
| Aztreonam | 26 (86.7%) | 26 (86.7%) | 7 (35%) |
| Amoxicillin/clavulanic acid | 9 (30%) | 6 (20%) | 2 (10%) |
| Ampicillin/sulbactam | 18 (60%) | 13 (43.3%) | 7 (35%) |
| Cefoperazone/sulbactam | 4 (13.3%) | 9 (30%) | 2 (10%) |
| Piperacillin/tazobactam | 9 (30%) | 6 (20%) | 2 (10%) |
| Imipenem | 4 (13.3%) | 4 (13.3%) | 0 |
| Meropenem | 4 (13.3%) | 4 (13.3%) | 0 |
| Ertapenem | 4 (13.3%) | 4 (13.3%) | 0 |
| Levofloxacin | 21 (70%) | 11 (36.7%) | 4 (20%) |
| Ciprofloxacin | 23 (76.7%) | 13 (43.3%) | 4 (20%) |
| Tetracycline | 26 (86.7%) | 21 (70%) | 9 (45%) |
| Doxycycline | 19 (63.3%) | 21 (70%) | 4 (20%) |
| Gentamicin | 12 (40%) | 11 (36.7%) | 4 (20%) |
| Amikacin | 5 (16.7%) | 4 (13.3%) | 2 (10%) |
| Sulfamethoxazole/trimethoprim | 26 (86.7%) | 19 (63.3%) | 9 (45%) |
| ESBL positive | 28 (93.3%) | 26 (86.7%) | 9 (45%) |
| CPO positive | 4 (13.3%) | 4 (13.3%) | 0 |
CD – Crohn's disease; ESBL – extended spectrum beta-lactamase, CPO – carbapenemase producing organism; UC – ulcerative colitis.